Factors such as the rising incidence of target infectious diseases and genetic disorders; increasing use of biomarker profiling for disease diagnostics; increasing investments, funds, and grants; technological advancements in PCR technologies and successful completion of the Human Genome Project are driving the growth of this market.
According to research report dPCR and qPCR market is projected to reach $7.6 billion by 2025, at a CAGR of 9.0% between 2020 and 2025.
Based on products & services, the qPCR market is categorized into instruments and software & services, reagents and consumables. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the growing private-public funding for life science research, expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time) and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).
Based on application, the market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications. The clinical applications segment is estimated to dominate the qPCR applications market in 2020. The key factors driving the market growth of cclinical applications segment include the rising incidence of infectious and genetic diseases, growing usage of qPCR in disease diagnosis and growing public emphasis on early & effective disease diagnosis & treatment.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
The prominent players operating in the dPCR and qPCR market are Bio-Rad Laboratories Inc. (US), Thermo Fisher Scientific (US) and F. Hoffmann-La Roche, Ltd. (Switzerland).